GENELUX Corp
GNLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001231457
In the last 90 days, GENELUX Corp insiders filed 0 open-market purchases and 7 sales; 72 institutions reported holding it in 13F filings for Q2 2026, worth $29.5M in total; no superinvestor holds it.
Holders of 5% or more of GNLX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of GENELUX Corp, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 13G | 9.99%4.22M shares | New | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
| Szalay Aladar | 13G/A | 8.20%3.13M shares | −0.20 ppfrom 8.40% | Jul 25, 20252 filings | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on GENELUX Corp, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20265:58 PM ET | Szalay Aladar | 13G/A | 8.20%3.13M shares | −0.20 ppfrom 8.40% | Dec 31, 2025 | SEC |
| Nov 14, 20256:44 PM ET | Armistice Capital, LLCand 1 other | 13G | 9.99%4.22M shares | New | Sep 30, 2025 | SEC |
| Jul 25, 20255:00 PM ET | Szalay Aladar | 13G/A | 8.40%3.17M shares | – | Jun 30, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell GENELUX Corp shares.
No Form 144 notices for GENELUX Corp are on file.